{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:16:31Z","timestamp":1791544591632,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jfma.2025.09.031","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:30:54Z","timestamp":1758947454000},"page":"S90-S95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S2","title":["Current status of HCV elimination in Taiwan"],"prefix":"10.1016","volume":"124","author":[{"given":"Rong-Nan","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7460-0564","authenticated-orcid":false,"given":"Maggie Shu-Mei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0927-1286","authenticated-orcid":false,"given":"Ya-Xin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Lun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.09.031_bib4","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis","year":"2022"},{"key":"10.1016\/j.jfma.2025.09.031_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.35772\/ghm.2021.01064","article-title":"Taiwan accelerated its efforts to eliminate hepatitis C","volume":"3","author":"Chien","year":"2021","journal-title":"Global Health Med"},{"key":"10.1016\/j.jfma.2025.09.031_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000690","article-title":"Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2025.09.031_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.09.031_bib11","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/liv.14412","article-title":"Taiwan is on track of accelerating hepatitis C elimination by 2025","volume":"40","author":"Wu","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2025.09.031_bib12","series-title":"Taiwan hepatitis C policy guidelines 2018-2025","year":"2019"},{"key":"10.1016\/j.jfma.2025.09.031_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","article-title":"Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants","volume":"106","author":"Chen","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.09.031_bib14","first-page":"605","article-title":"Incidence of hepatitis C infection in a hepatitis C endemic township in southern Taiwan","volume":"13","author":"Lu","year":"1997","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.09.031_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jmv.1097","article-title":"Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors","volume":"65","author":"Sun","year":"2001","journal-title":"J Med Virol"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2025.09.031_bib16","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jfma.2021.12.019","article-title":"Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: a nationwide survey in 2010-2018","volume":"121","author":"Lee","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.09.031_bib17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/infdis\/162.4.817","article-title":"Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.09.031_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","article-title":"Treatment of hepatitis C virus infection in patients with end-stage renal disease","volume":"26","author":"Liu","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.09.031_bib19","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1038\/s41598-021-87975-5","article-title":"Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan","volume":"11","author":"Lu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.09.031_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094791","article-title":"Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection","volume":"9","author":"Hsieh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.09.031_bib21","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/v14081637","article-title":"Collaborative referral model to achieve hepatitis C micro- elimination in Methadone maintenance treatment patients during the COVID-19 pandemic","volume":"14","author":"Tai","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2025.09.031_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139687","article-title":"National trend and characteristics of acute hepatitis C among HIV infected individuals: a matched case-control study-Taiwan, 2001-2014","volume":"10","author":"Lo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.09.031_bib23","article-title":"Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.09.031_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jfma.2011.06.022","article-title":"Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan","volume":"111","author":"Tseng","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.09.031_bib25","series-title":"Evaluate the population of chronic HCV and the efficacy of precision strategies in Taiwan. P-059, global hepatitis Summit, Los Angeles March 18-21","author":"Hsu","year":"2025"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2025.09.031_bib26","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1093\/infdis\/jiad016","article-title":"Policy and strategy of HCV elimination at national level: experience in Taiwan","volume":"228","author":"Chien","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.09.031_bib27","article-title":"A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles","author":"Hiebert-Suwondo","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:09:46Z","timestamp":1773126586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625005145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S0929664625005145"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.09.031","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of HCV elimination in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}